1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Immune Response BioPharma, Inc. Logo

Immune Response BioPharma, Inc. Provides Blockbuster RAVAX Phase III Study in RA Update

Immune Response BioPharma, Inc. Provides Blockbuster RAVAX Phase III Study in RA Update With Inadequate Response to Humira or Enbrel now Available at www.immuneresponse.net

PRLog - Jul. 5, 2012 - NEW YORK -- Immune Response BioPharma, Inc. Provides RAVAX Phase III Study in RA Update With Inadequete Response to Humira or Enbrel now Available online at www.immuneresponse.net or Skydrive Live @ https://skydrive.live.com/redir?resid=310AB990382AE320!126

Immune Response BioPharma, Inc. estimates we should be begin recruiting for the new Phase III RAVAX study by year end. Our IND should be filed within 60-90 days and the official trial should be uploaded to clinicaltrials.gov once finalized. The trial will test efficacy, safety and tolerance of RAVAX with Methotrexate for 12 months and a minimum of 500-1000 patients total who get the RAVAX drug. IRBP will first test RAVAX with Methotrexate with a sufficient amount of patients to fully access the first in class and best in class RA Vaccine. IRBP is targeting a minimum of 10% market share by 2016-2017 time frame.

"RAVAX is a game changer with a safe once a month dosing compared to current RA treatments such as Humira or Enbrel which our new study will help treat patients who fail those drugs. I would expect this trial to be oversubscribed once up and running and recruiting hopefully by year end. " IRBP CEO Mr. Buswell.

"Hopefully we enter into a corporate partnership rather quickly. Any pharma with current RA drugs  or those going off patent or any who don't have a potential blockbuster RA drug like RAVAX would be foolish to not partner with IRBP. RAVAX will create winners and losers in this space. The winners will be the corporate partner and of course patients" IRBP CEO Mr. Buswell.

"We are cautiously optimistic we complete a deal in the near future for our wonderful RA Vaccine treatment RAVAX. Additionally we believe RAVAX can be treatment of choice for RA patients under 10 years of diagnosed RA. We are actively discussing potential partnership opportunities with big pharma to co-develop RAVAX and fund the Phase III Study. I am confident IRBP will secure a corporate partner sooner rather than later for RAVAX and eventually get the first RA Vaccine through the clinical process and FDA approved to help those patients suffering from this debilitating disease" IRBP CEO Mr. Buswell.

Immune Response BioPharma, Inc. maybe found on the World WideWeb at www.immuneresponsebiopharma.com or our shorter URL @ www.immuneresponse.net             RAVAX Study Available @ https://skydrive.live.com/redir?resid=310AB990382AE320!126

--- End ---

Click to Share

Contact Email:
***@immuneresponsebiopharma.com Email Verified
Source:Immune Response BioPharma, Inc.
Phone:(917) 275-7931
Location:New York City - New York - United States
Industry:Biotech, Health
Tags:Rheumatoid Arthritis RA, immune response biopharma, Inc. Treatment, vaccine, drug
Last Updated:Jul 05, 2012
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Trending News...

  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
Click to Share